Exjade and Ultram drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Exjade (deferasirox) and Ultram (tramadol hydrochloride). Common drug interactions include tinnitus among females and abdominal pain among males.
The phase IV clinical study analyzes what interactions people have when they take Exjade and Ultram. It is created by eHealthMe based on reports of 38 people who take the same drugs from the FDA, and is updated regularly.
What is Exjade?
Exjade has active ingredients of deferasirox. It is often used in iron overload. eHealthMe is studying from 29,456 Exjade users. Check the latest studies of Exjade.
What is Ultram?
Ultram has active ingredients of tramadol hydrochloride. It is often used in pain. eHealthMe is studying from 28,425 Ultram users. Check the latest studies of Ultram.
38 people who take Exjade and Ultram together, and have interactions are studied.

What are the common drug interactions of Exjade and Ultram, by gender? *:
female:
- Tinnitus (a ringing in the ears)
- Unresponsive to stimuli
- Urinary bladder haemorrhage (urinary bladder bleeding)
- Blood bilirubin increased
- Haemorrhage urinary tract (bleeding from uterine)
- Transaminases increased
- Vomiting
- Aspartate aminotransferase increased
- Blood calcium decreased
- Bone loss
male:
- Abdominal pain
- Cough
- Wheezing (a high-pitched whistling sound made while you breath)
- Blood bilirubin increased
- Bone marrow failure
- Death
- Eye irritation
- Gastrointestinal carcinoma (cancer of stomach or intestine)
- Hepatic failure (liver failure)
- Metastatic neoplasm (spreadable cancer tumour)
What are the common drug interactions of Exjade and Ultram, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
- Bone loss
- Cerebral sarcoidosis (small areas of inflammation in brain)
- Hepatic enzyme increased
- Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
- Ill-defined disorder
- Multiple fractures
- Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
- Osteopenia (a condition where bone mineral density is lower than normal)
- Osteoporosis (bones weak and more likely to break)
40-49:
- Nausea (feeling of having an urge to vomit)
- Salivary hypersecretion (excess saliva secretion)
- Deafness neurosensory
- Tinnitus (a ringing in the ears)
- Blood bilirubin increased
- Bone marrow failure
- Hepatic failure (liver failure)
- Thrombocytopenia (decrease of platelets in blood)
- Aspartate aminotransferase increased
- Blood calcium decreased
50-59:
- Rash generalised (rash on most of body parts)
- Urosepsis (secondary infection that occurs when a urinary tract infection spreads to the bloodstream)
60+:
- Diarrhoea
- Visual impairment
- Fatigue (feeling of tiredness)
- Influenza
- Splenomegaly (enlargement of spleen)
- Thrombocytopenia (decrease of platelets in blood)
- Abdominal pain
- Acute respiratory failure
- Blood glucose increased
- Blood urea increased
What are the existing conditions these people have? *
- Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 12 people, 31.58%
- Serum Ferritin Increased: 4 people, 10.53%
- Nausea (feeling of having an urge to vomit): 4 people, 10.53%
- Urinary Tract Infection: 3 people, 7.89%
- Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 7.89%
- Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 3 people, 7.89%
- Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 7.89%
- Depression: 3 people, 7.89%
- Tumor: 3 people, 7.89%
- Haemochromatosis (body to absorb more iron than usual from food): 3 people, 7.89%
* Approximation only. Some reports may have incomplete information.
Do you take Exjade and Ultram?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Exjade and Ultram:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Exjade:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Ultram:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Exjade and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Ultram and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Mansour HM, "Tramadol and Disseminated Intravascular Coagulopathy: A Case Report", Medicine Science, 2015 Jan .
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
- Mansour HM, "Tramadol and Disseminated Intravascular Coagulopathy: A Case Report", Medicine Science, 2015 Jan .
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on deferasirox and tramadol hydrochloride (the active ingredients of Exjade and Ultram, respectively), and Exjade and Ultram (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Quetiapine Fumarate cause Belching? - 4 seconds ago
- Could Triumeq cause Osteoarthritis? - 4 seconds ago
- Could Isosorbide Mononitrate cause Muscle Cramps? - 6 seconds ago
- Tendonitis and Coronary Heart Disease - 9 seconds ago
- Could Metoclopramide cause Drug Screen Positive? - 9 seconds ago
- Could Folic Acid cause Vaginitis Bacterial? - 9 seconds ago
- Could Metoclopramide Hcl cause Pulmonary Embolism? - 12 seconds ago
- Could Lopurin cause Neutropenic Colitis? - 13 seconds ago
- Could Methotrexate cause Chest Pain? - 16 seconds ago
- Drug interactions of Xyzal and Reyataz - 17 seconds ago